Why the study?
To review the clinical aspects of osteosarcoma management and assess the role of 18F-FDG PET/CT, particularly in pediatric and young adult patients.
Does 18F-FDG PET/CT improve staging, recurrence detection, response monitoring, and prognostication in pediatric and young adult patients with osteosarcoma?
Does 18F-FDG PET/CT improve staging, recurrence detection, response monitoring, and prognostication in pediatric and young adult patients with osteosarcoma?
18F-FDG PET/CT is a useful imaging modality for the comprehensive management of osteosarcoma, including staging, response monitoring, and prognostication.
18F-FDG PET/CT supports osteosarcoma staging, recurrence detection, and response monitoring; leaves open prospective validation in pediatric patients.
Osteosarcoma is the most common type of primary malignant bone tumor. ¹⁸F-FDG PET/CT is useful for staging, detecting recurrence, monitoring response to neoadjuvant chemotherapy, and predicting prognosis. Here, we review the clinical aspects of osteosarcoma management and assess the role of ¹⁸F-FDG PET/CT, in particular with regard to pediatric and young adult patients.
No takes yet. Share an insight, caveat, or question.
Oh et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: